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Abstract 
Background: Atypical teratoid/rhabdoid tumor (AT/RT) is a highly malignant brain tumor that almost exclusively 
develops in young children. AT/RT belongs to the embryonal brain tumor group, comprising primitive tumors reca‑
pitulating the early development of the central nervous system during embryogenesis. The loss of SMARCB1 protein 
expression is a hallmark of AT/RT pathogenesis. LIN28A/B is a key gene in embryonic development and for the main‑
tenance of pluripotency in stem cells. LIN28B might be an important co‑player in AT/RT pathogenesis, considering 
the primitive nature and young age onset of AT/RT.
Methods: We explored the expression patterns of LIN28B in AT/RT and compared it with the expression in cortical 
dysplasia and medulloblastoma. The functional role of LIN28B was assessed using LIN28B‑siRNAs in primary cultured 
AT/RT cells.
Results: LIN28B is highly expressed in AT/RT compared with medulloblastoma and other embryonal tumors, whereas 
primary let‑7g miRNA is down‑regulated. AT/RT also showed higher expression of CCND1 and MYC, and lower expres‑
sion of CDKN1C. The suppression of CCND1 expression and enhanced expression of CDKN1C were also observed. The 
knockdown of LIN28B decreased cell viability and proliferation, induced cell cycle arrest, and reduced migration in pri‑
mary cultured AT/RT cells. Furthermore, we showed that the knockdown of LIN28B decreased the expression of other 
pluripotency‑related genes (OCT4 and NANOG) and the mesenchymal‑epithelial transition signature. We also trans‑
fected wild‑type SMARCB1 into primary cultured AT/RT cells. The restoration of SMARCB1 in AT/RT cells decreased the 
expression of LIN28B and CCND1.
Conclusions: These results show that LIN28B might be regulated through SMARCB1; the loss of SMARCB1 protein in 
AT/RT results in the unopposed expression of LIN28B and related oncogenes such as CCND1, leading to tumorigen‑
esis. Therefore, the strategic role of LIN28B in AT/RT might be utilized as an important therapeutic target.
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Background
Atypical teratoid/rhabdoid tumor (AT/RT) is a highly 
malignant brain tumor that predominantly develops in 
children. Despite dramatic improvements in treatments 
for other pediatric cancers, currently the prognosis of 
patients with AT/RT is dismal, with less than 10–20  % 
of patients attaining survival for more than 2  years [1]. 
Deletions and mutations of the SMARCB1 (BAF47/
SMARCB1/SNF5) gene are hallmarks of AT/RT tumors. 
SMARCB1 is a component of the SWI/SNF chromatin 
remodeling complex, and the loss of SMARCB1 function 
affects thousands of genes across the genome [2].
The biology contributing to the aggressiveness of AT/
RT remains elusive. In a previous study, we observed that 
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AT/RT brain tumor-initiating cells showed the robust 
expression of LIN28A/B when compared with other 
brain tumors, such as medulloblastoma and glioblas-
toma [3]. Additionally, recent studies have demonstrated 
that LIN28A/B are highly expressed in AT/RT primary 
tumors and cell lines, and the knockdown of LIN28A 
suppresses AT/RT growth and tumorigenicity [4]. The 
activation of LIN28A/B occurs in several different pri-
mary human tumors and plays an important role in can-
cer progression and metastasis [5, 6], involving stemness 
[7] through the negative regulation of the maturation of 
let-7 microRNA (miRNA) family members [8].
In the present study, we focused on LIN28B/let-7g 
and CCND1 for several reasons. First, LIN28B overex-
pression in human cancers has been frequently associ-
ated with human tumorigenesis compared with LIN28A 
[9, 10]. Second, several studies have demonstrated that 
LIN28B is a cytoplasmic protein shuttled into the nucleus 
in a cell-cycle dependent manner [5, 11, 12]. Third, a 
recent study showed that LIN28B promoted colon cancer 
migration and recurrence [8]. Human LIN28B recognizes 
let-7g [13]. We reported reciprocal expression between 
LIN28 and miRNA let-7g in AT/RT cells in a previous 
study [14].
In the present study, the expression and functional role 
of LIN28B in AT/RT was addressed. The inhibition of 
LIN28B expression increased let-7g expression, down-
regulated CCND1 and up-regulated CDKN1C. The 
knockdown of LIN28B decreased the proliferation and 
migration of AT/RT cells. Furthermore, the knockdown 
of LIN28B affected the expression of pluripotency- and 
mesenchymal-epithelial transition (EMT)-related genes. 
As the loss of function of SMARCB1 is a genetic hallmark 
of AT/RT, we explored the relationship of SMARCB1 
and LIN28B. The restoration of SMARCB1 expression 
in AT/RT cells suppressed LIN28B over expression and 
decreased cell proliferation.
These results indicate that LIN28B/let-7g/CCND1 
is a key factor in AT/RT tumorigenesis, and the loss of 
SMARCB1 leads to LIN28B overexpression.
Methods
Patients and tissue samples
Human brain tissues were collected from patients diag-
nosed with cortical dysplasia (CD; N = 4), medulloblas-
toma (MB; N  =  8) and AT/RT (N  =  10) who received 
surgery at the Seoul National University Children’s Hos-
pital (Table 1). Eligible patients and/or their parents pro-
vided written informed consent to donate tumor tissue 
samples. The Institutional Review Board (IRB) of the 
Seoul National University Hospital approved the tissue 
banking and study protocols (IRB # 1406-044-584). None 
of the patients received neo-adjuvant therapies. Tissue 
selection was determined based on tissue availability 
and a person blinded to the treatment outcome of the 
patients performed the selection.
Primary cell culture
Fresh AT/RT (from a 1-month-old boy: SNU-AT/RT3 and 
a 13-month-old boy: SNU-AT/RT4), MB (from a 7-year-
old boy) and glioblastoma (from a 43-year-old man) tis-
sues were obtained and enzymatically dissociated into 
single cells as previously described [3]. The tumor cells 
were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM; Life Technologies, Carlsbad, CA, USA) supple-
mented with 10 % fetal bovine serum (FBS; Life Technolo-
gies) and penicillin–streptomycin (Life Technologies). 
The primary cultured cells obtained from the AT/RT, MB 
and glioblastoma tissue samples were only used in early 
passages (<4) for experiments. The cells were incubated at 
37 °C with 5 % CO2 in a humidified atmosphere.
Real‑time quantitative reverse transcription polymerase 
chain reaction (RT‑qPCR)
Total RNA with miRNA was extracted from tissues 
(Table 1) and cells using a RNA isolation Kit (Life Tech-
nologies) according to the manufacturer’s instructions. 
Total RNA from the normal brain was purchased from 
Clontech Laboratories (Mountain View, CA, USA).The 
real-time RT-qPCR analysis of mRNA/mature miRNA 
was performed using the TaqMan mRNA or microRNA 
Assay Kit (Life Technologies) on an ABI 7000 system 
(Applied Biosystems, Foster City, CA, USA) according 
to the manufacturer’s instructions. TaqMan probes for 
LIN28A, LIN28B, SMARCB1, CCND1, CDKN1C, MYC, 
SOX2, OCT4, C-MYC, KLF4, glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH), primary-let-7g (pri-let-
7g), mature-let-7g and RUN6B were used. The reactions 
were performed under the conditions specified in the 
ABI TaqMan assay protocol. All reactions were repeated 
in triplicate, and the comparative threshold cycle (ΔCt) 
method was used to calculate the relative gene expres-
sion. The results were normalized to GAPDH for mRNA 
or RUN6B for miRNA and were presented relative to 
normal brain expression [15].
Immunohistochemistry
Paraffin-embedded tissues were acquired from CD, MB 
and AT/RT patients (Table  1). Immunohistochemistry 
with anti-LIN28A, anti-LIN28B, anti-CCND1 and anti-
CDKN1C antibodies (Abcam, Cambridge, MA, USA) 
was performed as previously described [15].
siRNA transfections
For LIN28B knockdown analysis, negative siRNA and 
two different sequences for LIN28B siRNA (LIN28B 
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siRNA-1 and LIN28B siRNA-2) were purchased from 
Bioneer (Daedeok-gu, Daejeon, Korea). The siRNA 
transfections were performed using Lipofectamine® 
RNAiMAX (Life Technologies) according to the manu-
facturer’s instructions.
SMARCB1 overexpression
To construct SMARCB1, full-length SMARCB1 was 
cloned into the mammalian expression vector pEGFP-C2 
(Clontech, CA, USA). The SMARCB1 coding sequence 
was PCR amplified using the forward (5′-CCCGAAG 
CTTCATGATGATGGCGCTGAGCAAG-3′) and reverse 
(5′-CCGGAATTCTTACCAGGCCGGGCCCGTGT 
TGGCA-3′) primers containing HindIII and EcoRI 
restriction sites. The constructs were verified through 
sequencing.
To generate cells expressing pEGFP-C2.SMARCB1, 
SNU-AT/RT3 and SNU-AT/RT4 cells were transfected 
using the Neon Transfection System (Life Technologies) 
as previously described [16]. The electroporation con-
ditions were 1400 V with a 20-pulse width and 1 pulse. 
The transfection efficiency was measured using a fluores-
cence microscope and confirmed in cell lysates using RT-
PCR and western blotting.
Western blotting
Total proteins were isolated from tissues and cells, the 
protein concentration was determined, and western blot 
analysis was performed as previously described [15]. Anti-
LIN28A (1:200; Cell Signaling Technology, Danvers, MA, 
USA), anti-LIN28B (1:200; Cell Signaling Technology), 
anti-CCND1 (1:1000; Thermo Fisher Scientific, Fremont, 
CA, USA) anti-CDKN1C (1:1000; Novus Biologicals, 
Littleton, CO, USA), and anti-β-actin (1:5000; Sigma-
Aldrich, St. Louis, MO, USA) antibodies were used.
Cell viability and proliferation assay
After transfecting the LIN28B siRNAs, the cytotoxic 
effects were determined using colorimetric cell count-
ing kit-8 (CCK-8; Dojindo Molecular Technologies, 
Rockville, MD, USA) and Roche Colorimetric Assay kit 
1 (BrdU labeling and detection kit III; Roche Diagnos-
tics GmbH, Germany) according to the manufacturer’s 
instructions. The absorbance of the samples against a 
background control was measured using a Microplate 
Reader (Molecular Devices, Sunnyvale, CA, USA) at a 
wavelength of 450 nm for CCK-8 and 575 nm for BrdU. 
The viability or proliferation of negative siRNA-treated 
cells was regarded as 100 %.
Table 1 Patient information
The tissues used for each experiment are marked
AT/RT atypical teratoid rhabdoid tumor
Designation Sex Age Diagnosis Frozen‑mRNA/miRNA Paraffin‑IHC Western blotting
C1 F 21 year Cortical dysplasia o o o
C2 F 16 year Cortical dysplasia o o o
C3 M 18 year Cortical dysplasia o o o
C4 M 14 year Cortical dysplasia o – –
M1 M 13 year Medulloblastoma o o o
M1 F 8 year Medulloblastoma o o o
M3 M 3 year Medulloblastoma o o o
M4 F 8 month Medulloblastoma o o o
M5 F 5 year Medulloblastoma o o o
M6 F 11 year Medulloblastoma o – o
M7 M 12 month Medulloblastoma o – –
M8 M 11 year Medulloblastoma o – –
A1 M 11 month AT/RT o o o
A2 F 13 month AT/RT o o o
A3 F 3 month AT/RT o o o
A4 M 1 year AT/RT o o o
A5 M 1 month AT/RT o o o
A6 M 12 month AT/RT o – o
A7 M 9 month AT/RT o – o
A8 M 13 month AT/RT o – o
A9 M 17 month AT/RT o – –
A10 M 1 month AT/RT o – –
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Cell cycle analysis
The LIN28B siRNA-transfected cells were harvested and 
fixed in 70  % alcohol overnight at −20  °C. After wash-
ing with phosphate-buffered saline (PBS), the cells were 
incubated with 0.2 mg/ml RNase (Sigma, St. Louis, MO, 
USA) at 37  °C for 30 min and subsequently 10 µg/ml of 
propidium iodide was added. At least 20,000 stained cells 
were analyzed, and the percentages of cells in G0/G1, S 
and G2/M phases were determined using a FACS Calibur 
flow cytometer (Becton–Dickinson, Franklin Lakes, NJ, 
USA).
Migration assay
After transfection, the cells were harvested in the serum-
free medium and introduced into the upper chamber 
(8-μm pore size, Corning, NY, USA). Culture medium 
supplemented with 10  % FBS were added to the lower 
chambers as the chemoattractant. After 24 h, the migra-
tion assays were performed as previously described [15].
Statistical analysis
All experiments are displayed as the mean  ±  standard 
deviation (SD) or expressed as a percentage of the con-
trols ±  SD. A two-tailed ANOVA assay and Student’s t 
test were used to determine the differences between data 
groups, and statistically significant differences were con-
sidered at p  <  0.05. GraphPad Prism software (La Jolia, 
CA, USA) was used for all the analyses. All experiments 
were conducted in triplicate.
Results
Amplification of LIN28B in AT/RT
We investigated the relative levels of LIN28A, LIN28B, 
pri-let-7g, mature let-7g, CCND1, and CDKN1C expres-
sion using RT-qPCR. The relative expression of LIN28A 
(3.8–156.9-fold; p  =  0.009), LIN28B (4.1–76.9-fold; 
p = 0.012) and CCND1 (5.7–126.0-fold; p = 0.009) were 
higher in AT/RT tissues, compared with cortical dyspla-
sia tissues, (Fig. 1; Table 2). The expression of pri-let-7g 
(0.4–1.9-fold; p  =  0.517), mature let-7g (0.0–0.3-fold; 
p =  1.000) and CDKN1C(0.2–9.1-fold; p =  0.864) were 
similar in AT/RT tissues. The expression of LIN28B 
(p = 0.008), CCND1 (p = 0.013), pri-let-7g (p = 0.007), 
and CDKN1C (p  =  0.036) were significantly higher in 
AT/RT tissues than in MB tissues. This difference was 
not observed for LIN28A (p = 0.441) and mature-let-7g 
(p = 0.075). We next examined protein expression using 
immunochemistry and western blot analysis. The results 
of immunohistochemistry showed that LIN28B protein 
expression was predominantly detected in AT/RT in MB 
tissues compared with LIN28A (Fig.  2a). The CCND1 
and CDKN1C expression patterns were mutually exclu-
sive in AT/RT and MB tissues. To further confirm these 
findings, we performed western blot analysis. The expres-
sion patterns of LIN28A, LIN28B, CCND1 and CDKN1C 
were remarkably similar to the RT-qPCR and immuno-
chemistry results (Fig.  2b). Taken together, these data 
show that the expression of LIN28B is more specific than 
LIN28A in AT/RT.
The knockdown of LIN28B in primary cultured AT/RT cells
To determine the role of LIN28B in AT/RT, we performed 
siRNA knockdown experiments using two distinct siRNA 
constructs (LIN28B siRNA-1 and LIN28B siRNA-2). The 
knockdown efficiency was confirmed using RT-qPCR 
and western blot analysis in two primary cultured AT/RT 
cell lines (SNU-AT/RT3 and SNU-AT/RT4). The LIN28B 
siRNAs effectively degraded LIN28B (LIN28B siRNA-1 
in SNU-AT/RT3, p  =  0.009; LIN28B siRNA-1 in SNU-
AT/RT4, p =  0.002; LIN28B siRNA-2 in SNU-AT/RT3, 
p = 0.001; LIN28B siRNA-2 in SNU-AT/RT4, p = 0.02; 
Fig.  3a; Additional file  1: Table S1). The inhibition of 
LIN28B suppressed CCND1 expression but enhanced 
CDKN1C expression (Fig. 3a; Additional file 1: Table S1). 
Western blot analysis after LIN28B siRNA treatment fur-
ther confirmed the RT-qPCR results (Fig. 3b; Additional 
file  1: Table S1). The increased expression of pri-let-7g 
and mature let-7g miRNA were observed after LIN28B 
knockdown (Fig. 3c; Additional file 1: Table S1).
Functional roles of LIN28B
To investigate the functional role of LIN28B, viability, 
proliferation, cell cycle, and migration of AT/RT cells 
were assessed after LIN28B knockdown. LIN28B knock-
down in AT/RT cells resulted in a significant reduction 
of cell viability and proliferation (Fig. 4a, b). Cell viabil-
ity was significantly reduced after LIN28 knockdown 
(negative siRNA vs. LIN28B siRNA-1 or LIN28B siRNA-
2: 100 ± 8.5 vs. 63.8 ± 2.8 or 65.7 ± 2.8 % in SNU-AT/
RT3, all p values  <0.001; 100  ±  0.8 vs. 56.7  ±  1.9 or 
56.0 ± 3.2 % in SNU-AT/RT4, all p values <0.001; Fig. 4a). 
Likewise, cellular proliferation was also significantly sup-
pressed (negative siRNA vs. LIN28B siRNA-1 or LIN28B 
siRNA-2: 100  ±  1.1 vs. 56.2  ±  5.2 or 58.0  ±  4.8  % in 
SNU-AT/RT3, all p values; 100 ±  1.0 vs. 58.0 ±  4.8 or 
44.0 ± 4.3 % in SNU-AT/RT4, all p values; Fig. 4b).
To determine whether LIN28B affects cell cycle, we 
compared cells treated with negative and LIN28B siR-
NAs. We observed that the inhibition of LIN28B induced 
cell cycle arrest, particularly at the G1 phase (negative 
siRNA versus LIN28B siRNA-1 or LIN28B siRNA-2: 
49.8  ±  2.7 vs. 63.7  ±  5.4 or 61.2  ±  2.1  % in SNU-AT/
RT3, all p values  <0.001; 52.3  ±  1.8 vs. 63.0  ±  4.4 or 
61.5 ± 0.6 % in SNU-AT/RT4, all p values <0.001; Fig. 4c).
Next, we further examined cell migration after LIN28B 
knockdown. The results of the transwell migration assay 
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showed that migration of AT/RT cells was significantly 
suppressed after LIN28B knockdown (comparison of 
migrated cells: negative siRNA vs. LIN28B siRNA-1 or 
LIN28B siRNA-2: 100 ± 7.2 vs. 30.2 ± 0.5 or 14.0 ± 2.3 % 
in SNU-AT/RT3, all p values  <0.001; 100  ±  20.2 vs. 
29.0  ±  9.0 or 17.6  ±  1.9  % in SNU-AT/RT4, all p val-
ues <0.001; Fig. 4d).
Changes of gene expression by LIN28B knockdown
LIN28B is a pluripotency-related gene that governs early 
embryogenesis. We investigated the expression of pluri-
potency-related genes, such as SOX2, OCT4, C-MYC, 
NANOG, and KLF4, after LIN28B knockdown in pri-
mary cultured AT/RT cells. The expression of NCAM, a 
marker of early neurogenesis, and β-actin were measured 
for comparison.
RT-qPCR analysis showed that expression of OCT4, 
MYC, NANOG, and KLF4 were decreased in SNU-AT/
RT3and SNU-AT/RT4 (Fig.  5a). The pattern of SOX2 
expression was variable, with an increase in SNU-AT/
RT3 and a decrease in SNU-AT/RT4. In SNU-AT/RT3, 
the increased expression of SOX2 and NCAM were 
observed after LIN28 siRNA treatment. This increase 
likely reflects enhanced neuroglia differentiation, as 
SOX2 is also a marker of immature glia and NCAM is a 
marker of early neurogenesis. To determine whether the 
suppression of LIN28B and other pluripotency-related 
genes leads to cellular differentiation, we confirmed the 
mRNA expression of GFAP, TUJ1 and O4 after LIN28B 
suppression (Fig. 5b). Although the changes in expression 
did not convey a solid pattern, general increase in the 
expression of differentiation markers were observed.
Fig. 1 Relative expression of mRNAs and miRNAs in cortical dysplasia (CD), medulloblastoma (MB) and AT/RT clinical samples. The relative expres‑
sion of LIN28A, LIN28B, pri‑let‑7g, mature let‑7g, CCND1, CDKN1C and MYC was detected using RT‑qPCR. The levels of Lin28B and CCND1were 
upregulated, while the levels ofpri‑let‑7g, and CDKN1C were significantly down‑regulated in AT/RT. The expression of LIN28B, rather than LIN28A, is 
more represented in AT/RT compared with CD and MB. *P < 0.05; **P < 0.01. Error bars represent ±SD
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Regulation of epithelial and mesenchymal cell‑related 
gene expression
The epithelial-mesenchymal transition (EMT) is associ-
ated with cancer cell migration and aggressiveness. After 
LIN28B knockdown, we examined the changes in EMT-
related marker expression, including epithelial mark-
ers (E-cadherin and ZO-1) and a mesenchymal marker 
(Vimentin). We observed that E-cadherin and ZO-1 
expression was increased and Vimentin expression was 
decreased in both AT/RT cell lines (Fig. 5c).
Restoration of SMARCB1expression in AT/RT cells
To determine whether SMARCB1 regulates LIN28B 
expression, we transfected pEGFP-C2.SMARCB1 into 
primary cultured AT/RT cells (Fig. 6a). Subsequently, we 
performed an immunoblot analysis of LIN28B, CCND1 
Table 2 RT-qPCR results for mRNA and miRNAs
The values are normalized to GAPDH or RUN6B
Designation LIN28A LIN28B CCND1 CDKN1C Pri‑let‑7g Mature let‑7g
C1 1.2 7.1 5.1 18.1 0.3 0.0
C2 1.0 4.2 3.7 2.1 0.3 0.0
C3 2.5 7.0 3.7 2.9 0.6 0.3
C4 1.5 3.2 4.3 2.5 0.2 0.1
M1 0.6 4.2 1.5 22.8 15.6 0.2
M1 4.1 36.4 0.3 50.1 6.0 0.0
M3 6.3 12.1 1.2 17.7 3.6 0.3
M4 56.7 0.4 0.2 4.7 2.4 0.2
M5 3.1 0.7 1.5 1.8 0.6 0.0
M6 106.0 2.2 16.1 19.4 5.0 0.3
M7 35.8 0.1 0.2 18.0 1.5 0.1
M8 31.9 4.0 0.4 2.7 1.3 0.7
A1 156.9 35.0 7.0 0.2 0.4 0.2
A2 53.5 38.9 19.8 3.1 0.5 0.2
A3 20.2 12.3 66.1 8.9 1.9 0.0
A4 3.8 15.3 5.7 0.7 0.1 0.1
A5 17.0 76.9 74.2 4.3 1.1 0.0
A6 24.3 7.5 18.9 9.3 1.6 0.1
A7 38.8 27.8 126.0 3.7 0.4 0.0
A8 10.1 4.1 54.3 0.5 0.3 0.0
A9 56.7 44.0 20.0 4.5 0.6 0.1
A10 26.6 65.5 57.3 5.2 0.5 0.3
Fig. 2 Comparison of the expression of LIN28A, LIN28B, SMARCB1, CCND1, and CDKN1C in CD, MB and AT/RT tissues. a Representative immunohis‑
tochemistry (IHC) images reveal the increased expression of LIN28A, LIN28B, and CCND1 and reduced expression of CDKN1C in AT/RT tissues. The 
loss of SMARCB1 expression was also observed in AT/RT, ×200. b The results of the western blot analysis were consistent with the IHC results
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and CDKN1C.The decreased expression of LIN28B and 
CCND1 and increased expression of CDKN1C were 
observed (Fig. 6b). Transfection of pEGFP-C2.SMARCB1 
reduced cell viability (pEGFP-C2 vs. pEGFP-C2.
SMARCB1: 100 ± 2.1 vs. 43.8 ± 2.3 % in SNU-AT/RT3, 
p = 0.0019; 100 ± 14.4 vs. 8.1 ± 1.5 % in SNU-AT/RT4, 
p < 0.001; Fig. 6c). We further investigated the expression 
of pluripotency-related genes using RT-qPCR in 2 AT/
RT cell lines and observed different expression levels of 
the genes. SMARCB1 expression significantly suppressed 
LIN28B gene expression in AT/RT cells (Fig.  6d). In 
SNU-AT/RT3 cells, KLF4 and OCT4 expression were 
increased, but the expression of LIN28A, SOX2 and MYC 
remained unchanged (Fig.  6d). In SNU-AT/RT-4 cells, 
LIN28A and OCT4 were increased, but SOX2, KLF4 and 
MYC expression was decreased (Fig.  6d). Interestingly, 
only OCT4 was elevated in both AT/RT cell lines.
Notably, the basal expression levels of SMARCB1 
were low in SMARCB1-competent cancers, such as 
glioblastoma and medulloblastoma. The knockdown of 
Fig. 3 Effect of LIN28B knockdown on AT/RT cells. The level of LIN28B mRNA and protein was effectively inhibited after the transfection of LIN28B‑
siRNAs. a RT‑qPCR and b western blot analysis showed that LIN28B knockdown reduced CCND1 expression and enhanced CDKN1C expression. c 
The increased expression of pre‑leg‑7g and mature let‑7g miRNA was observed after LIN28B knockdown. *P < 0.05; **P < 0.01; ***P < 0.01. Error bars 
represent ±SD
Fig. 4 Functional studies after LIN28B knockdown on AT/RT cells in vitro.LIN28B knockdown impacts AT/RT cell growth and migration. a–c 
Representative histograms showed that LIN28B inhibition reduced cell viability and cell proliferation, inducing cell cycle G1 arrest. d Representa‑
tive images and the quantification of migrated cells revealed the inhibition of AT/RT cell migration after LIN28B knockdown. ***P < 0.001. Error bars 
represent ±SD
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SMARCB1 using specific siRNAs in these primary cell 
lines yielded little changes in the expression of LIN28B, 
CCND1 and CDKN1C (Fig. 6e).
Discussion
AT/RT is one of the most aggressive and refractory can-
cers in humans. The most important characteristics of 
this disease are early-age onset and a typical genetic 
mutation. AT/RT predominantly develops during the 
infantile period, and the development of tumors in neo-
nates is not uncommon [1]. Tumor development in neo-
nates is a distinct feature of AT/RTs, as the peak age of 
diagnosis for patients with medulloblastoma is between 
5 and 9  years old. The loss of SMARCB1 expression 
through genetic mutation/deletion is another distinc-
tive feature of AT/RT [17]. This feature is highly spe-
cific for AT/RTs in pediatric neuro-oncology; the loss of 
SMARCB1 expression in immunohistochemistry strongly 
supports the diagnosis of AT/RT rather than medullo-
blastoma or choroid plexus carcinoma [18]. Intriguingly, 
a genome-wide analysis revealed that SMARCB1 aber-
ration is the only recurrent mutation observed in AT/
RT [19]. Indeed, AT/RT has the least number of gene 
mutations among human cancers [20] in contrast with 
the heavy mutation loads in adult-type cancers, such as 
glioblastomas [21]. Even medulloblastoma, which falls 
into the same group of embryonal brain tumor, shows the 
presence of ~10 recurrent genomic alteration per cancer 
[22]. For this reason, AT/RT is represented as a “true” 
embryonal tumor [23]. It is highly plausible that AT/RT 
has an activated embryonic/fetal gene expression pro-
gram for which the loss of SMARCB1 in AT/RT leads to 
alterations in gene expression. LIN28 is a RNA-binding 
protein that regulates the function of the let-7 miRNA 
Fig. 5 Regulation of pluripotent stem cell, differentiation and epithelial and mesenchymal cell‑related gene expression through LIN28B knock‑
down. a After LIN28B knockdown, all pluripotent stem cell‑related gene expression was reduced in SNU‑AT/RT4, and SOX2 and NCAM was 
increased in SNU‑AT/RT3. b The expression of GFAP, Tuj1 and O4 was variable in AT/RT cells. c The level of E‑cadherin and ZO‑1 was elevated and 
Vimentin was decreased in both AT/RT cell lines. Error bars represent ±SD
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family. The balance of LIN28 and let-7 miRNA is impor-
tant during embryonic development and for the mainte-
nance of embryonic stem cells. LIN28 and let-7 miRNA 
constitute a reciprocal regulatory loop, and the loss of 
LIN28 expression leads to cellular differentiation. In con-
trast, LIN28 overexpression has been observed in many 
advanced human cancers and is associated with poor 
prognosis [9]. Specifically, the overexpression of LIN28B 
has been observed in central nervous system primitive 
neuroectodermal tumors (PNETs) and AT/RT.
Present study shows that the overexpression of LIN28B 
is more specific for AT/RT, and there is no significant 
difference in LIN28A expression between AT/RT and 
medulloblastoma tissues. Therefore, we focused on the 
role of LIN28B in AT/RT pathogenesis. The knockdown 
of LIN28B expression suppressed cell viability and prolif-
eration, consistent with decreased CCND1 and enhanced 
CDKN1C expression. LIN28 is a pluripotency-related 
gene. Yu et  al. [24] reprogrammed human somatic cells 
into induced pluripotent stem cell lines using OCT4, 
SOX2, NANOG, and LIN28. The knockdown of LIN28B 
in AT/RT cells decreased the expression of pluripotency-
related factors and increased the expression of neuro-
glial differentiation markers. The variable responses of 
pluripotency- and differentiation-related genes reflect 
the heterogeneity and differentiation patterns of AT/RT 
tumors. AT/RT exhibits variable patterns of differentia-
tion, including neuroglial, epithelial, and mesenchymal 
lineages, making histopathological diagnosis challenging. 
EMT is a phenomenon observed in embryogenesis, and 
this cellular transition is considered crucial in cancer cell 
migration and invasion. The knockdown of LIN28B sig-
nificantly suppressed cell migration and the expression of 
mesenchymal phenotype (Vimentin and SNAIL1). Epi-
thelial markers (E-cadherin and ZO-1) were increased, 
confirming a reversal of the EMT process (so-called 
MET phenomenon) [25]. The loss of SMARCB1 func-
tion is a key event in AT/RT pathogenesis. SMARCB1 
is a component of the chromatic remodeling complex, 
which suppresses the expression of thousands of genes. 
The restoration of SMARCB1 expression in malignant 
rhabdoid tumor cells leads to cell cycle arrest and cel-
lular senescence [26]. In the present study, we intro-
duced SMARCB1 into AT/RT cell lines and observed the 
decreased expression of LIN28B, resulting in the disrup-
tion of CCND1-dependent cell proliferation. Interest-
ingly, the knockdown of SMARCB1 in glioblastoma and 
medulloblastoma generated little effect on the LIN28B 
Fig. 6 Overexpression of SMARCB1in AT/RT, MB and glioblastoma cells. a Transfection efficiency of SMARCB1 was confirmed using RT‑qPCR at 48 h 
after pEGFP‑C2.SMARCB1 transfection. b Transfection with pEGFP‑C2.SMARCB1 decreased LIN28B and CCND1 expression and increased CDKN1C 
expression. c Cell viability was significantly diminished after the introduction of SMARCB1. d LIN28B was suppressed and OCT4 was increased 
after the restoration of SMARCB1 expression in all AT/RT cells. However, the differential expression of LIN28A, SOX2, KLF4 and MYC was detected in 
all AT/RT cells. e In MB and glioblastoma, the expression of LIN28B, CCND1 and CDKN1C was unchanged after SMARCB1 knockdown. **P < 0.01; 
***P < 0.001. Error bars represent ±SD
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levels and the expression of CCND1 and CDKN1C. 
These results indicate that unlike truly embryonal 
tumors, such as AT/RT, SMARCB1-competent tumors 
are not dependent on the SMARB1-LIN28B pathway but 
rely on other signaling pathways for cellular survival and 
proliferation.
In conclusion, our results demonstrate that LIN28B 
might be regulated through SMARCB1, and the loss of 
SMARCB1 protein in AT/RT results in the unopposed 
expression of LIN28B and related oncogenes, such as 
CCND1, leading to tumorigenesis. Therefore, LIN28B 
may be a potential therapeutic target and biomarker of 
AT/RT for further clinical and translational studies.
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